Article type: Original Article

Novel Deep Learning Framework for Simultaneous Assessment of Left Ventricular Mass

and Longitudinal Strain: Clinical Feasibility and Validation in Patients with

Hypertrophic Cardiomyopathy

Jiesuck Park,[1,2] Yeonyee E. Yoon,[1,2,3*] Yeonggul Jang,[3*] Taekgeun Jung,[3] Youngtaek Hong,[3,4]

Seung-Ah Lee,[3,4] Hong-Mi Choi,[1,2] In-Chang Hwang,[1,2] Eun Ju Chun,[5,6] Goo-Yeong Cho,[1,2]

Hyuk-Jae Chang[3,4,7]

[1]Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, Seoul

National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea

[2]Department of Internal Medicine, Seoul National University College of Medicine, Seoul,

Republic of Korea

[3]Ontact Health Inc., Seoul, Republic of Korea

[4]CONNECT-AI Research Center, Yonsei University College of Medicine, Seoul, Republic of

Korea

[5]Department of Radiology, Cardiovascular Center, Seoul National University Bundang

Hospital, Seongnam, Gyeonggi-do, Republic of Korea

[6]Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of

Korea,

[7]Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of

Medicine, Yonsei University Health System, Seoul, Republic of Korea

Running title: DL-based LV volume, mass, and strain assessment

*Corresponding authors:

Yeonyee E. Yoon, MD, PhD

Professor, Division of Cardiology, Cardiovascular Center

Seoul National University Bundang Hospital

82, 173 Beon-gil, Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea

Phone: 82-31-787-7072

Email: yeonyeeyoon@snubh.org

And

Yeonggul Jang, PhD

Ontact Health Inc., Seoul, Republic of Korea

50-5, Ewhayeodae-gil, Seodaemun-gu, Seoul, Republic of Korea

Phone: 82-2-362-9610

1   E-mail: ygjang1722@yonsei.ac.kr

3   **Word count:** 3,630

ABSTRACT

Aims: This study aims to present the Segmentation-based Myocardial Advanced Refinement

Tracking (SMART) technique, a novel artificial intelligence (AI)-based approach for

transthoracic echocardiography (TTE) that incorporates motion tracking and left ventricular

(LV) myocardial segmentation throughout the cardiac cycle. The study evaluates its feasibility

and accuracy in assessing LV mass (LVM) and global longitudinal strain (LVGLS) in

hypertrophic cardiomyopathy (HCM) patients.

Methods and results: The study included 111 HCM patients (median age: 58 years, 69% male)

who underwent TTE and cardiac magnetic resonance imaging (CMR). SMART-derived

LVGLS (LVGLS$_{SMART}$) showed strong correlation with conventional manual LVGLS

measurements (LVGLS$_{TTE-EchoPAC}$; Pearson's correlation coefficient [PCC] 0.851; mean

difference 0 [-2–0]). When compared to CMR as the reference standard for LVM measurement

(LVM$_{CMR}$), conventional dimension-based TTE calculations (LVM$_{TTE-DB}$) overestimated LVM

compared to CMR (PCC 0.652; mean difference: 106 [90–123]), while LVM$_{SMART}$

demonstrated excellent agreement with CMR (PCC 0.843; mean difference: 1 [-11–13]). For

predicting extensive LGE (≥15% of LVM), LVGLS$_{SMART}$ and LVM$_{SMART}$ exhibited comparable

predictive performance (AUC: 0.72 and 0.66, respectively) to conventional LVGLS and CMR.

Patients identified as high-risk for extensive LGE by LVGLS$_{SMART}$ (≤11%) and LVM$_{SMART}$

(≥166g) had significantly higher rates of adverse outcomes, including heart failure

hospitalization, new-onset atrial fibrillation, and defibrillator implantation.

Conclusion: The SMART technique provides a comparable evaluation of LVGLS and a more

accurate assessment of LVM compared to conventional TTE, with additional predictive value

for myocardial fibrosis and adverse outcomes, supporting its utility in HCM management.

Keywords: cardiac magnetic resonance imaging; echocardiography; global longitudinal strain;

hypertrophic cardiomyopathy; left ventricle; mass.

1. INTRODUCTION

Transthoracic echocardiography (TTE) is the primary diagnostic tool for hypertrophic cardiomyopathy (HCM).(1) Evaluation of HCM typically involves assessing left ventricular (LV) hypertrophy and function through visual estimation and quantitative measurements, such as LV wall dimensions and ejection fraction (EF).(2) However, this conventional approach is operator-dependent, time-consuming, and often incomplete. In particular, the thickened LV wall in HCM reduces cavity size, leading to overestimation of EF, making LV global longitudinal strain (LVGLS) a more accurate measure of myocardial contractility. Furthermore, dimension-based LV mass (LVM) calculation fails to accurately reflect asymmetric characteristics of LV hypertrophy in HCM.(3, 4) Consequently, cardiac magnetic resonance (CMR) is often required for a more precise evaluation.(1)

Recent advances in artificial intelligence (AI) have enabled automated segmentation of LV cavity and wall, providing LV volume, EF, and mass in TTE.(5-7) Automated LVGLS measurement is also now available and validated across various populations.(8, 9) However, the unique geometry of HCM complicates the automated detection of LV endocardial and epicardial borders, as well as accurate motion tracking. Consequently, validation of AI-based automated measurements remains limited in HCM, particularly in accurately measuring LVLVM in cases with asymmetric hypertrophy.

Our research group has previously developed and validated a comprehensive automated system for TTE analysis,(10-15) featuring an algorithm that simultaneously segments the LV wall and tracks myocardial motion, validated in myocardial infarction patients.(14) Building on this, we developed the Segmentation-based Myocardial Advanced Refinement Tracking (SMART) technique, which refines motion tracking using LV myocardial

1　segmentation throughout the cardiac cycle. In this study, we aimed to present the SMART

2　technique and evaluate its ability to successfully segment and track the LV wall in HCM

3　patients, enabling accurate assessment of LVM and LVGLS.

2. METHODS

2.1. Study Population

The AI-based system utilized in this study was developed and validated with data from the Open AI Dataset Project (AI-Hub), which was initiated by the Ministry of Science and ICT, Korea.(10-16) For the development of the SMART technique, no additional developmental datasets were required beyond those used in the original automatic segmentation and strain analysis.(14) (**Supplemental Method 1**) We conducted in-house validation of the SMART technique across diverse study populations, including the internal test set, an American population, and a paired dataset with both TTE and CMR. (**Supplemental Method 1**)

In this study, to further evaluate the feasibility and accuracy of our novel SMART technique in HCM, we used data from a previous study cohort of 111 patients with HCM who underwent both TTE and CMR within a 6-month at Seoul National University Bundang Hospital between 2010 and 2019.(17) The clinical diagnosis of HCM was established by identifying a maximal end-diastolic wall thickness >15 mm in any segment of the LV, with other potential causes of hypertrophy excluded. The study protocol was approved by the Institutional Review Board of Seoul National University Bundang Hospital (IRB No. B-2305-827-002), with a waiver of informed consent granted due to the retrospective study design. All clinical data were fully anonymized prior to analysis. The study was conducted in accordance with the principles outlined in the Declaration of Helsinki (2013).

2.2. TTE Acquisition and Analysis

All echocardiographic examinations were performed by trained echocardiographers or

cardiologists and interpreted by board-certified cardiologists with expertise in echocardiography, following current guidelines. Standard ultrasound machines (Vivid 7, E9, and E95; GE Vingmed Ultrasound AS, Norway) were used with a 2.5-MHz probe at 50 to 80 Hz frame rates. Following standard protocols, 2-dimensional (2D), M-mode, and Doppler images were obtained.

LV maximal wall thickness ($LVMWT_{TTE}$) was measured at the thickest segment of the LV wall in end-diastole (ED). Dimension-based LVM (LVM_{TTE-DB}) was calculated using the interventricular septum (IVS), left ventricular internal diameter (LVID), and posterior wall thickness (PWT) in ED according to the *Devereux* equation (3):

$$0.8 \times 1.04 \times [(IVS + LVID + PWT)3 - LVID3] + 0.6\,g$$

LV ED and end-systolic (ES) volumes ($LVEDV_{TTE}$, and $LVESV_{TTE}$, respectively) were measured from the apical 4-chamber view (A4C) and apical 2-chamber view (A2C) to calculate LVEF using the Simpson biplane method.(2) Tissue Doppler imaging was used to assess the early mitral annular velocity (e') at the septal side of the mitral annulus.

LVGLS analysis was performed by an imaging specialist, using two different software programs: TomTec Image Arena 4.6 (Munich, Germany) for endocardial tracking ($LVGLS_{TTE-Tomtec}$) and EchoPAC PC BT20 (GE Medical Systems, Norway) for mid-myocardial tracking ($LVGLS_{TTE-EchoPAC}$). Both analyses utilized the same TTE image frames focusing on the LV. All echocardiographic images were saved as DICOM files and analyzed on dedicated workstations. The region of interest was semiautomatically delineated at the end-systolic frame on apical views, which then tracked speckles along the endocardial border throughout the cardiac cycle. The peak negative strain value from each myocardial segment was recorded as the segment's peak longitudinal systolic strain, and the LVGLS for each image plane was

calculated by averaging the segmental values. The final LVGLS was derived by averaging the

LVGLS from the apical 3-chamber (A3C), A4C, and A2C views. For ease of interpretation, the

LVGLS values were converted to absolute values.

2.3. CMR Acquisition and Analysis

CMR images were acquired using either a 1.5-T system (Intera CV release 10; Philips

Healthcare, Amsterdam, Netherlands) or a 3-T system (Philips Ingenia; Best, Netherlands).

Imaging was performed under electrocardiographic gating and breath-hold conditions. Steady-

state free-precession (SSFP) cine-CMR images were obtained in the horizontal long axis,

vertical long axis, and LV outflow tract. A short-axis stack view of the whole LV was obtained

for LV volume and mass analysis. The cine-CMR sequence was acquired at 25-30 frames/R-R

interval (field of view, 320-370 mm; repetition time/echo time, 3.0-3.6/1.5-1.8ms; flip angle,

45-60°; and slice thickness, 6-8 mm). Late gadolinium enhancement (LGE) images were

obtained 10 minutes after intravenous administration of 0.2 mmol/kg of gadodiamide

(Omniscan; GE Healthcare, Princeton, NJ, USA) using a phase-sensitive inversion-recovery

turbo field echo sequence (repetition/echo time: 4.5–4.6/1.3–1.5ms, flip angle: 20–25°, slice

thickness: 8 mm).

All acquired images were processed using CVI42 software (version 5.10; Circle

Cardiovascular Imaging, Calgary, Canada) and analyzed by an independent radiologist blinded

to clinical and echocardiographic data. LV volumes ($LVEDV_{CMR}$ and $LVESV_{CMR}$), $LVEF_{CMR}$,

and LVM_{CMR} were estimated from short-axis cine-CMR. LVGLS analysis was conducted via

CMR tissue-tracking ($LVGLS_{CMR-TT}$), which uses a mid-surface curvilinear coordinate system

to track myocardial deformation and follows the motion of software-generated myocardial

nodes on SSFP cine sequences.(18) Endocardial and epicardial borders were traced in a semi-automated fashion, with manual correction for contours with apparent deviation. Using long-axis cine-images, the whole myocardial LVGLS was calculated throughout the cardiac cycle by the software. As with TTE-derived LVGLS values, the peak negative value (peak systolic strain) was converted to an absolute value, designated as $LVGLS_{CMR-TT}$. LGE mass was quantified using the full-width at half-maximum method. The total LGE mass was obtained by summing the LGE from all sections, and the relative extent of LGE was expressed as a percentage of total LVM. Extensive LGE was defined as involving >15% of LVM, a threshold associated with an increased risk of sudden cardiac death (SCD).(1, 17, 19)

2.4. AI-based System for Automatic TTE Analysis

Our AI-based system (Sonix Health Workstation, version 2.0; Ontact Health Inc., Korea) perform fully automated tasks, including view classification, segmentation, and echocardiographic parameter extraction.(10, 13-15) However, since TTE views for GLS measurement were pre-selected for comparison with two conventional LVGLS analysis system in the previous study,(17) view classification was not conducted separately in this study.

2.5. Segmentation-based Myocardial Advanced Refinement Tracking (SMART)

The SMART technique is a novel technique that combines myocardial segmentation with speckle tracking to improve the accuracy of LV quantification in 2D TTE. Integrating structural information allows for precise measurement of important LV functional metrics like LVEDV, LVESV, LVM, and LVGLS. This approach addresses limitations of traditional speckle tracking

methods, which often have difficulty accurately tracking endocardial and epicardial borders in the presence of trabeculations or ultrasound artifacts such as shadows and reverberation. Moreover, traditional 2D speckle tracking often struggles to capture complex 3-dimensional (3D) motion components, such as longitudinal, circumferential, and radial movements, resulting in errors in strain estimation.

Recent advancements in segmentation models that utilize convolutional neural networks (CNNs) and vision transformers (ViTs) allow accurate the LV wall and cavity delineation across diverse patient populations. (20-22) These models effectively capture structural nuances and correlate highly with manual LV volume measurements, improving boundary detection and quantification of LVM and function. In the SMART framework, speckle tracking begins with estimated motion vectors, refined using segmentation-based information to better align with myocardial structures. (**Figure** 1) This refinement involves a two-step process applied to the updated region of interest (ROI) curve, with adjustments made based on a raster scan along its normal direction. In the first step, the ROI's mid-myocardial line is refined to reflect the underlying myocardial structure more accurately. In the second step, the epicardial and endocardial borders are adjusted to ensure precise delineation of the LV wall. This integration enhances the accuracy of endocardial and epicardial border tracking and ROI delineation, resulting in more reliable strain measurement and simultaneous assessment of LV volume and mass. Detailed methodology is provided in **Supplemental Method 2.**

The SMART framework employs advanced tracking and segmentation techniques to accurately calculate LV volume and mass by delineating endocardial and epicardial borders throughout the cardiac cycle. These borders are extracted for every frame in the A4C, A2C, and A3C views. This process generates geometric parameters, such as LV radius and myocardial

thickness, at the basal, mid, and apical levels. LV volumes are computed using a tri-planar configuration (A4C-A2C-A3C), which combines ellipsoid fitting along three axes for precise volume calculations. LV volume is derived from the endocardial border (LVEDV$_{SMART}$, and LVESV$_{SMART}$); LVM (LVM$_{SMART}$) is calculated as the difference between epicardial and endocardial volumes multiplied by a myocardial tissue density of 1.05. This method enables precise LVM estimation through detailed geometrical modelling of the LV wall.

In-house validation results of the SMART technique in the internal test datasets, the American population, and a paired dataset with both TTE and CMR are detailed in **Supplemental Methods 3-5**.

2.5. Statistical analysis

The concordance between LVGLS derived from SMART technique and two different conventional software programs were assessed using the Pearson Correlation Coefficient (PCC) and mean absolute error (MAE). The agreement was further evaluated through Bland-Altman analysis, reporting the mean difference and limits of agreement. Similarly, LVMWT$_{TTE}$, LVM$_{TTE-DB}$, and LVM$_{SMART}$ were compared against LVM$_{CMR}$, the ground truth. Discrimination performance for extensive LGE (>15% LVM) was evaluated across different LVGLS and LVMWT and LVM methods using the area under the receiver operating characteristic curves (AUC). Optimal cutoffs for LVGLS$_{SMART}$ and LVM$_{SMART}$ were obtained from receiver operating characteristics (ROC) curves to predict extensive LGE, enabling patient stratification. Clinical outcomes, including heart failure admission, new-onset atrial fibrillation (AF), and new implantable cardioverter-defibrillators (ICD) insertion, were analyzed as a composite endpoint. Survival curves and Cox regression analysis, adjusted for age, sex, body mass index,

1 systolic blood pressure, LVEF, and e' velocity, were used to compare outcome risks and

2 calculate hazard ratios (HR). Statistical analyses were performed using R software (version

3 4.3.2; R Development Core Team, Vienna, Austria), with two-sided p-values <0.05 considered

4 statistically significant.

3. RESULT

3.1. Baseline Characteristics

Table 1 summarizes the baseline characteristics of 111 HCM patients (median age: 58 years, male 69%). Among them, 41 (37%) had mixed or diffuse type HCM, 37 (33%) had septal type HCM, and 33 (30%) had apical type HCM. Additionally, 16 patients (14%) exhibited extensive LGE. While age, sex, and BMI did not significantly differ between patients with and without extensive LGE, those with extensive LGE had a higher prevalence of mixed or diffuse HCM phenotypes.

LVEDV and LVESV values, regardless of the measurement method, were similar across groups. However, LVEF measured by TTE, whether by conventional manual measurement or the SMART technique, was lower in patients with extensive LGE. Interestingly, LVEF measured by CMR showed no significant difference between the groups. In contrast, LVGLS was significantly reduced in patients with extensive LGE, regardless of the measurement method, indicating more impaired LV function. This reduction was observed with EchoPAC ($LVGLS_{TTE-EchoPAC}$, 11% vs. 14%, p=0.002), TomTec ($LVGLS_{TTE-TomTec}$, 16% vs. 20%, p=0.001), the SMART technique ($LVGLS_{SMART}$, 11% vs. 14%, p=0.005), and CMR ($LVGLS_{CMR-TT}$, 10% vs 11%, p<0.001). Conventional LVM measures, such as $LVMWT_{TTE}$ and LVM_{TTE}-$_{DB}$, showed no significant differences between patients with and without extensive LGE. However, LVM_{SMART} was significantly higher in patients with extensive LGE (161 g vs. 133 g; p=0.037) as was LVM_{CMR} (188 g vs. 123 g; p=0.007).

3.2. Performance of SMART Technique

The differences between methods for LVGLS measurement are summarized in **Table 2**. The correlation plot demonstrates $LVGLS_{SMART}$ is well correlated with LVGLS by conventional vendors. (**Figure 2**) Specifically, since $LVGLS_{SMART}$ track the mid-myocardium, it showed higher concordance $LVGLS_{TTE-EchoPAC}$ (mean difference, 0 [-1 to 0]; p for difference=0.312). In contrast, $LVGLS_{SMART}$ tended to be lower compared to $LVGLS_{TTE-TomTec}$, which tracks the endocardium (mean difference, -6 [-7 to -6]; p for difference <0.001). When compared to $LVGLS_{CMR}$, all TTE-based LVGLS values showed significant differences (p for difference <0.001); however, $LVGLS_{SMART}$ exhibited the smallest discrepancy (mean difference, $LVGLS_{SMART}$; 2 [1 to 3], $LVGLS_{TTE\_EchoPAC}$; 3 [2 to 3], and $LVGLS_{TTE\_TomTec}$; 9 [8 to 10]). The correlation plots are provided in **Supplemental Result 1**.

For LVEDV and LVESV, measurements automatically obtained using SMART technique tended to be larger compared to conventional manual measurements in TTE (mean difference, LVEDV; 11 [4 to 19], and LVESV; 7 [4 to 9]). Interestingly, this adjustment reduced the well-known underestimation of LV volumes by TTE compared to CMR (mean difference, $LVEDV_{SMART}$; -27 [-33 to -21] vs. $LVEDV_{TTE}$; -37 [-44 to -31], and $LVESV_{SMART}$; -3 [-6 to -0] vs. $LVESV_{TTE}$; -10 [-13 to -7]), showing slightly improved alignment with CMR values through the SMART technique. As a result, $LVEF_{SMART}$ tended to be slightly lower compared to both conventional manually measured $LVEF_{TTE}$ (mean difference, -3 [-5 to -2]) and $LVEF_{CMR}$ (mean difference, -7 [-9 to -4]).

3.3. Feasibility of LVM Measurement by SMART Technique

Using LVM_{CMR} as the reference, we examined the correlation of $LVMWT_{TTE}$ and LVM_{TTE_DB}, which are commonly used indices for assessing the severity of LV hypertrophy in conventional

TTE analysis. The correlations are shown in **Figure 3**. Although LVM_{TTE-DB} showed better correlations with LVM_{CMR} compared to $LVMWT_{TTE}$, there remained a significant difference (mean difference 106 [90 to 123]; p for difference <0.001). In contrast, unlike LVM_{TTE-DB}, which fails to account for asymmetric hypertrophy, LVM_{SMART} estimates LVM by delineating the epicardial and endocardial borders of the LV wall from the apical views. As a result, it not only demonstrated improved correlation (PCC 0.843 [0.779 to 0.890], p<0.001) but also showed excellent agreement with LVM_{CMR} (mean difference, 1 [-11 to 13], p for difference = 0.903).

3.4. Predictive Value of SMART based LVGLS and LVM for Extensive LGE

We performed ROC curve analysis to assess whether extensive LGE (>15% of LVM) observed on CMR could be predictive using $LVGLS_{SMART}$. The AUC was 0.72 (0.58 to 0.86), comparable to other TTE-based LVGLS values (AUC 0.75 [0.64 to 0.86] for $LVGLS_{TTE-EchoPAC}$, p for difference =0.708; AUC 0.75 [0.62 to 0.88] for $LVGLS_{TTE-TomTec}$, p for difference =0.693) and showing no significant difference compared to $LVGLS_{CMR}$ (AUC 0.78 [0.68 to 0.88], p for difference =0.212). (**Figure 4**) Similarly, we evaluated whether indices used for assessing LV hypertrophy could predict extensive LGE. Conventional TTE-based metrics showed limited predictive ability (AUC 0.59 [0.43 to 0.74] for $LVMWT_{TTE}$; AUC 0.57 [0.39 to 0.74] for LVM_{TTE-DB}). However, when LVM was measured using the SMART technique, the AUC increased to 0.66 (0.51 to 0.82), which was comparable to LVM_{CMR} with no significant difference observed (AUC 0.71 [0.56 to 0.86], p for difference =0.130).

3.5. Outcome Risk Stratification Based on Extensive LGE Predicted by Auto-Measured

LVGLS and LVM

The optimal cutoff values for extensive LGE were identified as 11% for LVGLS$_{SMART}$ and 166

g for LVM$_{SMART}$. Patients categorized as high-risk for extensive LGE based on LVGLS$_{SMART}$

(≤11%) had a significantly higher risk of adverse clinical outcomes, with an adjusted HR of

6.02 (2.21 to 16.41). (**Figure 5**) Similarly, those classified as high-risk based on LVM$_{SMART}$

(≥166 g) also demonstrated an increased risk of clinical outcomes, with an adjusted HR of 3.97

(1.50 to 10.47).

4. DISCUSSION

In this study, we introduce the SMART technique, a novel approach that refines motion tracking by incorporating LV myocardial segmentation throughout the cardiac cycle. We demonstrated that the SMART technique is feasible and effectively segments LV walls in HCM patients, enabling accurate assessment of LVM and LVGLS. For predicting extensive LGE, LVGLS$_{SMART}$ showed predictive value comparable to LVGLS measured by well-stablished systems, while LVM$_{SMART}$ demonstrated superior predictive value compared to conventional TTE measures such as LVMWT$_{TTE}$ or LVM$_{TTE-DB}$. Additionally, we confirmed the independent prognostic value of both LVGLS$_{SMART}$ and LVM$_{SMART}$.

Conventional speckle tracking system often relies on semi-automated, operator-defined endocardial border delineation, whether tracking the endocardium or mid-myocardium. While effective for assessing global LV motion, this approach does not precisely define both endocardial and epicardial borders to establish an ROI for tracking. Recently, AI-based automatic LV strain analysis has been introduced, enabling automatic segmentation and tracking of the LV wall.[8, 14, 22] Salte et al. demonstrated the feasibility and accuracy of automated LVGLS measurement in 200 patients with various cardiovascular pathologies and levels of LV function, using DL-based LV wall segmentation and mid-wall tracking.[8] They later reported improved precision and reproducibility with this approach.[22] Another study involving 870 COVID-19 patients showed that AI-derived LVEF and LVGLS, based on LV endocardial border tracing, had superior accuracy in predicting mortality compared to manual measurement.[23] We recently presented a system that automatic segments the LV wall to define and track the mid-wall, enabling accurate LVEF and LVGLS measurement.[14] In revascularized STEMI patients, our system accurately measured LVEF and LVGLS compared

to manual measurements and demonstrated comparable prognostic value. However, most of these studies focused on patients with varying levels of LV dysfunction and did not specifically address LV hypertrophy. The ability of DL-based techniques to accurately delineate the endocardial and epicardial borders and track LV myocardial motion in HCM patients, characterized by severe and asymmetric LV hypertrophy, remains insufficiently validated.

Accurate tracking of LV wall motion requires precise and automated segmentation, which is particularly challenging in TTE due to lower tissue contrast, susceptibility to artifacts, and limited resolution compared to CMR. This aligns with the well-documented challenge of accurately quantifying LV wall hypertrophy in HCM using TTE. For instance, prior studies have reported discrepancies between LVMWT measured by CMR and TTE.(24, 25) Moreover, conventional TTE-derived LVM, which relies on geometric assumptions, often fails to capture asymmetric hypertrophy pattern, such as those seen in septal or apical HCM, as demonstrated in the present study. In contrast, the SMART technique addresses these limitations by integrating accurate LV wall segmentation from A4C, A2C, and A3C views to refine speckle tracking. This approach provides a more precise representation of LV structure, even in cases with asymmetric geometry, resulting in LVM_{SMART} showing high concordance with LVM_{CMR}. Given the critical prognostic value of LVM in HCM, the ability to automatically and accurately measure LVM using TTE carries significant clinical implications. In our study, LVM_{SMART}, unlike $LVMWT_{TTE}$ or LVM_{TTE-DB}, successfully predicted extensive LGE and demonstrated independent prognostic value.

The SMART technique's precise LV segmentation and integration of tri-plane imaging improved the accuracy of LV volume measurements, reducing discrepancies with CMR-derived volumes compared to conventional bi-plane assessment. While Simpson's biplane

method is more accurate than dimension-based approaches, it still relies on geometric

assumptions about LV shape (2), which are well-documented to result in 2D TTE

underestimating LV volumes compared to CMR.(26, 27) These assumptions introduce

inaccuracies in cases with anatomical variability, such as slanted basal segments, cross-

sectional ellipticity, or foreshortened planes.(28) These challenges are further amplified in

HCM due to asymmetric hypertrophy. Although TTE-based measurement of LV volume,

including the SMART technique, has inherent limitations compared to CMR, the SMART

technique's enhanced LV wall segmentation and tri-plane approach offer significant

improvements over conventional 2D TTE analysis.

Even with fully automated LV segmentation without manual intervention, the SMART

technique demonstrated high accuracy for measuring LVGLS. By performing segmentation

across all frames, rather than being limited to ES, SMART refines motion tracking and enables

precise LVGLS measurement. The SMART-derived LVGLS showed strong concordance with

LVGLS manually measured by experts using well-established systems. Notably, since the

SMART technique employs mid-wall tracking, its results align more closely with those from

the EchoPAC system, which also uses mid-wall tracking, than with TomTec system, which

relies on endocardial tracking. The concordance with CMR was lower, as expected, due to

differences in imaging modalities and examination dates. While TTE-derived LVGLS

measurements were obtained from the same views of the same echocardiographic exam using

different methods, $LVGLS_{CMR-TT}$ was measured on the cine-CMR conducted on a separate day

with non-identical imaging planes. Despite these differences, $LVGLS_{SMART}$ demonstrated

predictive ability for extensive LGE comparable to $LVGLS_{CMR}$ and also showed independent

prognostic value.

Despite these promising results, several limitations need to be acknowledged. Although this study demonstrated the feasibility of the SMART technique in HCM, the sample size was relatively small. Nevertheless, the study cohort included a unique structure incorporating LV geometric and three different LVGLS parameters derived from both TTE and CMR, allowing for a robust comparison of SMART's performance against these imaging modalities. Future research involving a more diverse population of cardiomyopathy subtypes, beyond HCM, is necessary to further validate the diagnostic feasibility and clinical applicability of the SMART technique.

5. CONCLUSION

The SMART technique is an AI-based novel technique that combines LV speckle tracking with myocardial segmentation in a hybrid approach based on TTE. In patients with HCM, characterized by LV hypertrophy with asymmetric geometry, the SMART technique allows for comparable evaluation of LVGLS and more accurate assessment of LVM compared to conventional measurements in TTE. Furthermore, SMART-derived LVGLS and LVM demonstrated utility in predicting myocardial fibrosis and clinical outcomes, supporting the diagnostic and prognostic feasibility of this novel technique in the management of HCM.

Contributors

All authors contributed equally to this study. All authors have read and approved the final version of the manuscript. J.P, J.J, and Y.E.Y verified the underlying data of the current study.

Data Sharing Statement

Data cannot be made publicly available due to ethical restrictions set by the IRB of the study institution; i.e., public availability would compromise patient confidentiality and participant privacy. Please contact the corresponding author (yeonyeeyoon@gmail.com) to request the minimal anonymised dataset. Researchers with additional inquiries about the deep learning model presented in this study are also encouraged to reach out to the corresponding author.

Declaration of Interests

Y.E.Y, Y.J., Y.H., and S.A.L. are currently affiliated with Ontact Health, Inc. H.J.C. holds stock in Ontact Health, Inc. The other authors have no conflicts of interest to declare.

Funding

This work was supported by a grant from the Institute of Information & communications Technology Planning & Evaluation (IITP) funded by the Korea government (Ministry of Science and ICT) (No.2022000972, Development of a Flexible Mobile Healthcare Software Platform Using 5G MEC); and the Medical AI Clinic Program through the NIPA funded by the MSIT. (Grant No.: H0904-24-1002).

Reference

1. Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(23):e1239-e311.

2. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39 e14.

3. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450-8.

4. Kristensen CB, Myhr KA, Grund FF, Vejlstrup N, Hassager C, Mattu R, et al. A new method to quantify left ventricular mass by 2D echocardiography. Sci Rep. 2022;12(1):9980.

5. Zhang J, Gajjala S, Agrawal P, Tison GH, Hallock LA, Beussink-Nelson L, et al. Fully Automated Echocardiogram Interpretation in Clinical Practice. Circulation. 2018;138(16):1623-35.

6. Yoon YE, Kim S, Chang HJ. Artificial Intelligence and Echocardiography. J Cardiovasc Imaging. 2021;29(3):193-204.

7. Zhou J, Du M, Chang S, Chen Z. Artificial intelligence in echocardiography: detection, functional evaluation, and disease diagnosis. Cardiovasc Ultrasound. 2021;19(1):29.

8. Salte IM, Ostvik A, Smistad E, Melichova D, Nguyen TM, Karlsen S, et al. Artificial

Intelligence for Automatic Measurement of Left Ventricular Strain in Echocardiography. JACC Cardiovasc Imaging. 2021;14(10):1918-28.

9.	Kwan AC, Chang EW, Jain I, Theurer J, Tang X, Francisco N, et al. Deep Learning-Derived Myocardial Strain. JACC Cardiovasc Imaging. 2024;17(7):715-25.

10.	Jeon J, Ha S, Yoon YE, Kim J, Jeong H, Jeong D, et al. Echocardiographic view classification with integrated out-of-distribution detection for enhanced automatic echocardiographic analysis. arXiv [eess.SP; 2023]. Available from: https://arxiv.org/abs/2308.16483.

11.	Jeon J, Kim J, Jang Y, Yoon YE, Jeon D, Hong Y, et al. A Unified Approach for Comprehensive Analysis of Various Spectral and Tissue Doppler Echocardiography. arXiv [eess.IV; 2023]. Available from: https://arxiv.org/abs/2311.08439.

12.	Jeong D, Jung S, Yoon YE, Jeon J, Jang Y, Ha S, et al. Artificial intelligence-enhanced automation for M-mode echocardiographic analysis: ensuring fully automated, reliable, and reproducible measurements. Int J Cardiovasc Imaging. 2024;40(6):1245-56.

13.	Park J, Jeon J, Yoon YE, Jang Y, Kim J, Jeong D, et al. Artificial intelligence-enhanced automation of left ventricular diastolic assessment: a pilot study for feasibility, diagnostic validation, and outcome prediction. Cardiovascular Diagnosis and Therapy. 2024;14(3):352-66.

14.	Jang Y, Choi H, Yoon YE, Jeon J, Kim H, Kim J, et al. An Artificial Intelligence-Based Automated Echocardiographic Analysis: Enhancing Efficiency and Prognostic Evaluation in Patients With Revascularized STEMI. Korean Circ J. 2024;54(11):743-56.

15.	Park J, Kim J, Jeon J, Yoon YE, Jang Y, Jeong H, et al. Artificial Intelligence-Enhanced Comprehensive Assessment of the Aortic Valve Stenosis Continuum in Echocardiography. medRxiv 2024.07.08.24310123. Available from: https://doi.org/10.1101/2024.07.08.24310123.

16. Agency NIS. Open AI Dataset Project (AI-Hub) [Available from: https://aihub.or.kr/.

17. Park J, Yoon YE, Chun EJ, Choi HM, Hwang IC, Lee HJ, et al. Endocardial versus whole-myocardial tracking global longitudinal strain analysis in patients with hypertrophic cardiomyopathy: A preliminary comparative study. PLoS One. 2023;18(7):e0288421.

18. Yoon YE, Kang SH, Choi HM, Jeong S, Sung JM, Lee SE, et al. Prediction of infarct size and adverse cardiac outcomes by tissue tracking-cardiac magnetic resonance imaging in ST-segment elevation myocardial infarction. Eur Radiol. 2018;28(8):3454-63.

19. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484-95.

20. Duffy G, Cheng PP, Yuan N, He B, Kwan AC, Shun-Shin MJ, et al. High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning. JAMA Cardiol 2022;7(4):386–95.

21. Wei H, Ma J, Zhou Y, Xue W, Ni D. Co-learning of appearance and shape for precise ejection fraction estimation from echocardiographic sequences. Med Image Anal 2023;84:102686.

22. Christensen M, Vukadinovic M, Yuan N, Ouyang D. Vision-language foundation model for echocardiogram interpretation. Nat Med. 2024;30(5):1481-8.

22. Salte IM, Ostvik A, Olaisen SH, Karlsen S, Dahlslett T, Smistad E, et al. Deep Learning for Improved Precision and Reproducibility of Left Ventricular Strain in Echocardiography: A Test-Retest Study. J Am Soc Echocardiogr. 2023;36(7):788-99.

23. Asch FM, Descamps T, Sarwar R, Karagodin I, Singulane CC, Xie M, et al. Human versus Artificial Intelligence-Based Echocardiographic Analysis as a Predictor of Outcomes:

An Analysis from the World Alliance Societies of Echocardiography COVID Study. J Am Soc Echocardiogr. 2022;35(12):1226-37.e7.

24.   Urbano-Moral JA, Gonzalez-Gonzalez AM, Maldonado G, Gutierrez-Garcia-Moreno L, Vivancos-Delgado R, De Mora-Martin M, et al. Contrast-Enhanced Echocardiographic Measurement of Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy: Comparison with Standard Echocardiography and Cardiac Magnetic Resonance. J Am Soc Echocardiogr. 2020;33(9):1106-15.

25.   Hindieh W, Weissler-Snir A, Hammer H, Adler A, Rakowski H, Chan RH. Discrepant Measurements of Maximal Left Ventricular Wall Thickness Between Cardiac Magnetic Resonance Imaging and Echocardiography in Patients With Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2017;10(8):e006309.

26.   Rigolli M, Anandabaskaran S, Christiansen JP, Whalley GA. Bias associated with left ventricular quantification by multimodality imaging: a systematic review and meta-analysis. Open Heart. 2016;3(1):e000388.

27.   Manole S, Budurea C, Pop S, Iliescu AM, Ciortea CA, Iancu SD, et al. Correlation between Volumes Determined by Echocardiography and Cardiac MRI in Controls and Atrial Fibrillation Patients. Life (Basel). 2021;11(12):1362.

28.   Kim WC, Beqiri A, Lewandowski AJ, Puyol-Anton E, Markham DC, King AP, et al. Beyond Simpson's Rule: Accounting for Orientation and Ellipticity Assumptions. Ultrasound Med Biol. 2022;48(12):2476-85.

Figure Legends

Figure 1. Workflow of the SMART Framework: Integrating Motion Tracking and

Segmentation for LV Quantification

The workflow highlights the dynamic update of LV ROI using a bi-directional dense motion

field and a segmentation-guided refinement process to achieve myocardial structure-aware

tracking for enhanced functional assessment. The process begins with segmentation of the LV

myocardium across all frames, constructing an LV area curve for cardiac cycle analysis,

including the identification of key phases such as ED and ES. Motion vectors are estimated

and iteratively refined through a two-step process: first, by aligning the mid-myocardial line

with the myocardial structure, and second, by precisely delineating the epicardial and

endocardial borders.

Abbreviations: ED, end-diastole; ES, end-systole; LV, left ventricle; ROI, region of interest;

SMART, Segmentation-based Myocardial Advanced Refinement Tracking.

Figure 2. Concordance of LVGLS between SMART and manual measurements

The correlation plot demonstrated a significant association between SMART and manual

measurements for LVGLS using conventional vendors (EchoPAC (A) and TomTec (B)).

Abbreviations as in Figure 1: LVGLS, left ventricular global longitudinal strain; MAE, mean

absolute error; PCC, Pearson Correlation Coefficient; TTE, transthoracic echocardiography.

Figure 3. Concordance of SMART and conventional dimension-based measurement to

CMR for LVM

Compared to LVMWT (A) and dimension-based LVM (B) measured by TTE, SMART-based LVM (C) showed stronger concordance LVM assessed by CMR.

Abbreviations as in Figure 1 and 2: CMR, cardiovascular magnetic resonance imaging; DB, dimension-based methods; LVM, left ventricular mass; LVMWT, left ventricular maximal wall thickness.

Figure 4. Predictive value of SMART-based LVM and LVGLS for extensive LGE

Compared to conventional vendors, SMART-based LVGLS showed comparable performance for predicting extensive LGE (A). SMART-based LVM outperformed LVMWT and dimension-based LVM for predicting extensive LGE (B).

Abbreviations as in Figure 1-3: AUC, area under the receiver operating characteristic curves; CI, confidence interval

Figure 5. Outcome Risk Stratification Based on SMART-based LVM and LVGLS

Stratification based on SMART-based LVGLS ($\leq$11%) (A) and LVM ($\geq$166g) (B) identified high-risk patients for composite outcomes.

Abbreviations as in Figure 1-4: HR, hazard ratio

Supplemental Methods

Supplemental Method 1. Dataset for the Development of the SMART Technique

Supplemental Method 2. Technical Detail of the SMART Technique

Supplemental Method 3. In-House Validation of SMART-Derived LV Volume and GLS Measurements

Supplemental Method 4. External Validation of the SMART-Derived GLS Measurement in American Population

Supplemental Method 5. Comparison of SMART Technique with Conventional TTE and CMR Measurement in a Dataset with Paired Echocardiography and CMR Imaging

Supplemental Results

Supplemental Result 1. Concordance of SMART and conventional vendors to CMR for LVGLS

Abbreviations: CMR, cardiovascular magnetic resonance imaging; LVGLS, left ventricular global longitudinal strain; MAE, mean absolute error; PCC, Pearson Correlation Coefficient; SMART, Segmentation-based Myocardial Advanced Refinement Tracking; TTE, transthoracic echocardiography.

Figure 1. The SMART framework

Tracking (backward)

LV ROI
Initialization

Tracking (forward)

ED

ES

ED

SMART: Segmentation-based Myocardial Advanced Refinement Tracking

[Step 1] Motion-based ROI Tracking

Update LV ROI
using motion vector

Motion field

[Step 2] Refinement with Segmentation

Refine mid myocardial line
and epi / endo border

Figure 2. Concordance of LVGLS between SMART and manual measurements

A. LVGLS$_{SMART}$ vs. LVGLS$_{TTE-EchoPAC}$

PCC = 0.851 (0.790–0.895), p<0.001
MAE = 1.2%

B. LVGLS$_{SMART}$ vs. LVGLS$_{TTE-TomTec}$

PCC = 0.679 (0.564–0.768), p<0.001
MAE = 1.7%

Figure 3. Concordance of SMART and manual measurement to CMR for LV mass

A. LVM_{CMR} vs. $LVMWT_{TTE}$

PCC = 0.524 (0.374–0.647), p<0.001

B. LVM_{CMR} vs. LVM_{TTE-DB}

PCC = 0.652 (0.531–0.748), p<0.001
MAE = 32.9g

C. LVM_{CMR} vs. LVM_{SMART}

PCC = 0.843 (0.779–0.890), p<0.001
MAE = 22.7g

Figure 4. Predictive value of SMART-based LV mass and LVGLS for extensive LGE

A. LVGLS

	AUC (95% CI)	P
LVGLS_TTE-EchoPAC	0.75 (0.64–0.86)	0.002
LVGLS_TTE-TomTec	0.75 (0.62–0.88)	0.001
LVGLS_SMART	0.72 (0.58–0.86)	0.005
LVGLS_CMR	0.78 (0.68–0.88)	<0.001

B. LVMAT and LVM

	AUC (95% CI)	P
LVMWT_TTE	0.59 (0.43–0.74)	0.261
LVM_TTE-DB	0.57 (0.39–0.74)	0.389
LVM_SMART	0.66 (0.51–0.82)	0.037
LVM_CMR	0.71 (0.56–0.86)	0.007

Figure 5. Outcome Risk Stratification Based on SMART-based LV mass and LVGLS